In:
Cancer, Wiley, Vol. 125, No. 11 ( 2019-06), p. 1830-1836
Abstract:
The current phase 1 trial of lenalidomide added to the combination of dose‐adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin with rituximab (DA‐EPOCH‐R) in patients with double‐hit lymphoma and diffuse large B‐cell lymphoma with dual overexpression of MYC and BCL2 identified 15 mg of lenalidomide as the recommended phase 2 dose. All 10 patients with dual‐expression lymphomas achieved a complete metabolic response and remained free of disease after a median follow‐up of 28 months.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
Language:
English
Publisher:
Wiley
Publication Date:
2019
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
1429-1
Permalink